Light Sciences Oncology Overview
- Founded
- 1994
- Status
- Out of Business
- Employees
- 17
- Latest Deal Type
- Out of Business
Light Sciences Oncology General Information
Description
Developer of a water-soluble drug designed to treat solid tumors. The company's Talaporfin Sodium drug is a water-soluble drug targeted by a small, single-use and disposable drug activator, enabling patients to get repeatable and non-invasive treatment treatments.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
- 12600 South East 38th Street
- Suite 111
- Bellevue, WA 98006
- United States
+1 (425) 000-0000
Light Sciences Oncology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Out of Business | 01-Jul-2019 | 00000 | Completed | Out of Business | ||
| 9. Later Stage VC | 10-Jan-2019 | 00.000 | 00000 | Completed | Generating Revenue | |
| 8. Later Stage VC | 20-Dec-2013 | 00000 | 00000 | Completed | Generating Revenue | |
| 7. Later Stage VC | 23-Jan-2012 | 000.00 | 00000 | Completed | Generating Revenue | |
| 6. Grant | 02-Nov-2010 | 00000 | 00000 | Completed | Generating Revenue | |
| 5. Later Stage VC (Series C) | 16-Jul-2008 | 000.00 | 00000 | 00000 | Completed | Generating Revenue |
| 4. IPO | 08-Feb-2008 | 000.00 | Cancelled | Generating Revenue | ||
| 3. Debt - General | 31-Dec-2007 | 0000 | 00000 | Completed | Generating Revenue | |
| 2. Later Stage VC (Series B) | 11-Jul-2007 | $30M | $100M | 00000 | Completed | Generating Revenue |
| 1. Later Stage VC (Series A) | 14-Dec-2005 | $70M | $70M | 000.00 | Completed | Generating Revenue |
Light Sciences Oncology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | 0,000,000 | 00.00 | 00.00 | 00.00 | 00.00 | 000 | ||
| Series B | 0,000,000 | 00.00 | 00.00 | 00.00 | 00.00 | 0.000 | ||
| Series A | 13,429,989 | $0.4 | $5 | $5 | $8 | 17.52% |
Light Sciences Oncology Patents
Light Sciences Oncology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20110008372-A1 | Enhancement of light activated drug therapy through combination with other therapeutic agents | Abandoned | 08-Jul-2009 | 0000000000 | 0 |
| US-20100036311-A1 | Enhancement of light activated therapy by immune augmentation using anti-ctla-4 antibody | Granted | 06-Aug-2008 | 00000000000 | 0 |
| US-20110236402-A1 | Enhancement of light activated therapy by immune augmentation using anti-ctla-4 antibody | Granted | 06-Aug-2008 | 00000000000 | 0 |
| US-7993640-B2 | Enhancement of light activated therapy by immune augmentation using anti-ctla-4 antibody | Active | 06-Aug-2008 | 00000000000 | 0 |
| US-8226946-B2 | Enhancement of light activated therapy by immune augmentation using anti-ctla-4 antibody | Active | 06-Aug-2008 | A61K41/0038 | 00 |
Light Sciences Oncology Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialLight Sciences Oncology Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000 00000000 | 29-Dec-2006 | 0000000000 | Therapeutic Devices | ||
| Light Sciences | 29-Dec-2006 | Merger/Acquisition | Biotechnology | 0000 0000 |